Biotech Funding Surge in September 2025: uniQure, Dianthus, Mineralys Lead
September 2025 witnessed a surge in biotech funding, with multiple companies securing substantial investments. uniQure, Dianthus Therapeutics, and Mineralys Therapeutics took the lead, each raising over $200 million.
uniQure, a pioneer in gene therapy, raised $345 million from a public offering. This will finance the potential commercial launch of its lead candidate AMT-130 for Huntington's disease. Dianthus Therapeutics also raised $288 million in a public offering to advance its preclinical and clinical development activities. Meanwhile, Mineralys Therapeutics secured $287.5 million from a public offering to fund clinical development of its lead candidate lorundrostat.
Crystalys Therapeutics launched with a significant $205 million in series A funding. The company aims to revolutionize gout treatment. Treeline Biosciences raised $200 million in a series A round, bringing its total funding to $1.1 billion. Odyssey Therapeutics raised the largest private biotech round in September 2025, with $213 million in series D funding.
Regionally, European companies raised $253.8 million from six private biotech rounds. North American companies raised $1.032 billion from eight private biotech rounds, while Asia-Pacific companies raised $109.4 million from three private biotech rounds.
Bioweg, a European company, secured 16 million euros in a Series A funding round led by Axeleo Capital. This supports commercialization and expansion in Europe. However, no other specific companies with comparable financing amounts in public rounds during September 2025 were identified in the search results.
September 2025 proved to be a month of substantial biotech funding, with several companies securing large investments. The largest funding rounds were led by uniQure, Dianthus Therapeutics, and Mineralys Therapeutics. These funds will support clinical development, commercial launches, and expansion, potentially bringing new treatments to patients and driving innovation in the biotech sector.
